GlaxoSmithKline Plc has reported positive Phase 2 data for an antibody-drug conjugate directed against multiple myeloma and announced plans to make regulatory filings later this year. The drug, belantamab mafodotin, showed a clinically meaningful overall response rate in patients with the disease, GSK announced on 23 August.
DREAMM-2 enrolled 223 patients with relapsed multiple myeloma who had not responded to other treatments such as an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody. The two-arm study met its primary endpoint of overall response.